vs
Medpace Holdings, Inc.（MEDP）与Ryman Hospitality Properties, Inc.（RHP）财务数据对比。点击上方公司名可切换其他公司
Medpace Holdings, Inc.的季度营收约是Ryman Hospitality Properties, Inc.的1.1倍（$708.5M vs $664.6M），Medpace Holdings, Inc.净利率更高（19.1% vs 10.4%，领先8.6%），Medpace Holdings, Inc.同比增速更快（32.0% vs 13.2%），过去两年Medpace Holdings, Inc.的营收复合增速更高（17.7% vs 4.1%）
Medpace Holdings, Inc.是总部位于美国俄亥俄州辛辛那提的全球性临床研究机构（CRO），现有员工约6000人。公司采用全服务运营模式，可提供全球中心实验室、影像核心实验室、生物分析实验室服务，且在总部临床研究园区内设有I期临床试验单元。
莱曼酒店地产是一家主营酒店、度假村、娱乐及媒体业务的企业，得名于旗下位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾为俄克拉荷马出版公司子公司时期，1983年收购WSM公司后奠定现代业务基础，同时将知名演出IP大奥普里等核心资产纳入麾下。
MEDP vs RHP — 直观对比
营收规模更大
MEDP
是对方的1.1倍
$664.6M
营收增速更快
MEDP
高出18.9%
13.2%
净利率更高
MEDP
高出8.6%
10.4%
两年增速更快
MEDP
近两年复合增速
4.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $708.5M | $664.6M |
| 净利润 | $135.1M | $69.4M |
| 毛利率 | — | — |
| 营业利润率 | 21.6% | 20.7% |
| 净利率 | 19.1% | 10.4% |
| 营收同比 | 32.0% | 13.2% |
| 净利润同比 | 15.5% | 10.1% |
| 每股收益（稀释后） | $4.65 | $1.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEDPRHP
| Q1 26 | — | $664.6M | ||
| Q4 25 | $708.5M | $737.8M | ||
| Q3 25 | $659.9M | $592.5M | ||
| Q2 25 | $603.3M | $659.5M | ||
| Q1 25 | $558.6M | $587.3M | ||
| Q4 24 | $536.6M | $647.6M | ||
| Q3 24 | $533.3M | $550.0M | ||
| Q2 24 | $528.1M | $613.3M |
净利润MEDPRHP
| Q1 26 | — | $69.4M | ||
| Q4 25 | $135.1M | $74.5M | ||
| Q3 25 | $111.1M | $34.9M | ||
| Q2 25 | $90.3M | $71.8M | ||
| Q1 25 | $114.6M | $63.0M | ||
| Q4 24 | $117.0M | $72.3M | ||
| Q3 24 | $96.4M | $59.0M | ||
| Q2 24 | $88.4M | $100.8M |
毛利率MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | — | 41.4% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 49.7% | ||
| Q1 25 | — | 44.4% | ||
| Q4 24 | — | 40.4% | ||
| Q3 24 | — | 43.1% | ||
| Q2 24 | — | 48.4% |
营业利润率MEDPRHP
| Q1 26 | — | 20.7% | ||
| Q4 25 | 21.6% | 19.4% | ||
| Q3 25 | 21.5% | 15.0% | ||
| Q2 25 | 20.9% | 21.1% | ||
| Q1 25 | 20.3% | 19.8% | ||
| Q4 24 | 23.4% | 18.6% | ||
| Q3 24 | 21.1% | 19.3% | ||
| Q2 24 | 19.9% | 27.4% |
净利率MEDPRHP
| Q1 26 | — | 10.4% | ||
| Q4 25 | 19.1% | 10.1% | ||
| Q3 25 | 16.8% | 5.9% | ||
| Q2 25 | 15.0% | 10.9% | ||
| Q1 25 | 20.5% | 10.7% | ||
| Q4 24 | 21.8% | 11.2% | ||
| Q3 24 | 18.1% | 10.7% | ||
| Q2 24 | 16.7% | 16.4% |
每股收益（稀释后）MEDPRHP
| Q1 26 | — | $1.03 | ||
| Q4 25 | $4.65 | $1.12 | ||
| Q3 25 | $3.86 | $0.53 | ||
| Q2 25 | $3.10 | $1.12 | ||
| Q1 25 | $3.67 | $1.00 | ||
| Q4 24 | $3.67 | $1.12 | ||
| Q3 24 | $3.01 | $0.94 | ||
| Q2 24 | $2.75 | $1.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $497.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $459.1M | $770.8M |
| 总资产 | $2.0B | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | $497.0M | $471.4M | ||
| Q3 25 | $285.4M | $483.3M | ||
| Q2 25 | $46.3M | $420.6M | ||
| Q1 25 | $441.4M | $413.9M | ||
| Q4 24 | $669.4M | $477.7M | ||
| Q3 24 | $656.9M | $534.9M | ||
| Q2 24 | $510.9M | $498.4M |
股东权益MEDPRHP
| Q1 26 | — | $770.8M | ||
| Q4 25 | $459.1M | $750.2M | ||
| Q3 25 | $293.6M | $758.5M | ||
| Q2 25 | $172.4M | $800.4M | ||
| Q1 25 | $593.6M | $531.5M | ||
| Q4 24 | $825.5M | $549.0M | ||
| Q3 24 | $881.4M | $551.9M | ||
| Q2 24 | $763.6M | $562.6M |
总资产MEDPRHP
| Q1 26 | — | $6.2B | ||
| Q4 25 | $2.0B | $6.2B | ||
| Q3 25 | $1.8B | $6.2B | ||
| Q2 25 | $1.6B | $6.1B | ||
| Q1 25 | $1.9B | $5.2B | ||
| Q4 24 | $2.1B | $5.2B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $1.9B | $5.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.7M | — |
| 自由现金流经营现金流 - 资本支出 | $188.1M | — |
| 自由现金流率自由现金流/营收 | 26.6% | — |
| 资本支出强度资本支出/营收 | 0.6% | — |
| 现金转化率经营现金流/净利润 | 1.43× | — |
| 过去12个月自由现金流最近4个季度 | $681.9M | — |
8季度趋势，按日历期对齐
经营现金流MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | $192.7M | $164.7M | ||
| Q3 25 | $246.2M | $205.2M | ||
| Q2 25 | $148.5M | $122.5M | ||
| Q1 25 | $125.8M | $98.2M | ||
| Q4 24 | $190.7M | $166.6M | ||
| Q3 24 | $149.1M | $218.1M | ||
| Q2 24 | $116.4M | $184.3M |
自由现金流MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | $188.1M | $58.5M | ||
| Q3 25 | $235.5M | $135.4M | ||
| Q2 25 | $142.4M | $53.0M | ||
| Q1 25 | $115.8M | $-14.5M | ||
| Q4 24 | $183.0M | $76.0M | ||
| Q3 24 | $138.5M | $85.7M | ||
| Q2 24 | $103.5M | $78.8M |
自由现金流率MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | 26.6% | 7.9% | ||
| Q3 25 | 35.7% | 22.9% | ||
| Q2 25 | 23.6% | 8.0% | ||
| Q1 25 | 20.7% | -2.5% | ||
| Q4 24 | 34.1% | 11.7% | ||
| Q3 24 | 26.0% | 15.6% | ||
| Q2 24 | 19.6% | 12.9% |
资本支出强度MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 14.4% | ||
| Q3 25 | 1.6% | 11.8% | ||
| Q2 25 | 1.0% | 10.5% | ||
| Q1 25 | 1.8% | 19.2% | ||
| Q4 24 | 1.4% | 14.0% | ||
| Q3 24 | 2.0% | 24.1% | ||
| Q2 24 | 2.4% | 17.2% |
现金转化率MEDPRHP
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 2.21× | ||
| Q3 25 | 2.22× | 5.88× | ||
| Q2 25 | 1.65× | 1.71× | ||
| Q1 25 | 1.10× | 1.56× | ||
| Q4 24 | 1.63× | 2.30× | ||
| Q3 24 | 1.55× | 3.70× | ||
| Q2 24 | 1.32× | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
RHP
| Food and beverage | $289.3M | 44% |
| Rooms | $223.8M | 34% |
| Entertainment | $79.2M | 12% |
| Other | $72.3M | 11% |
